Disorders of Gut Microbiota and Plasma Metabolic Profiles May Be Associated with Lymph Node TuberculosisOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study investigated whether gut microbiota composition and plasma metabolic profiles are altered in lymph node tuberculosis (LNTB), a form of tuberculosis whose relationship with gut microbiota had not previously been explored. Researchers used metagenomic sequencing to characterize gut microbial diversity and composition, paired with plasma metabolomics to assess circulating metabolite changes. KEGG pathway analysis was applied to link microbial gene content to metabolic function, focusing especially on short-chain fatty acid (SCFA) biosynthesis. An integrated analysis then examined correlations between specific gut bacteria and plasma metabolites in LNTB.
Who was studied?
The abstract does not report specific participant numbers, ages, or geographic setting. It indicates a comparison between individuals diagnosed with lymph node tuberculosis (the LNTB group) and healthy individuals serving as controls. Samples analyzed included gut microbiota (via metagenomic sequencing) and plasma (via metabolomics) from these two groups.
What were the most important findings?
LNTB patients showed significantly altered gut microbial diversity, with notable reductions in SCFA-producing taxa including Ruminococcus, Faecalibacterium, Roseburia, and Blautia compared to healthy individuals. KEGG pathway analysis indicated that this gut dysbiosis negatively affected SCFA biosynthesis and metabolism. Plasma metabolomics revealed disruptions in metabolites tied to SCFA synthesis and inflammation pathways, and integrated analysis found significant correlations between taxa such as Blautia, Butyricicoccus, Coprococcus, Ruminococcus, Bacteroides, and Clostridium and plasma metabolites including alpha-benzylbutyric acid, acetic acid, and succinic acid.
What are the greatest implications of this study?
The findings suggest that gut microbiota dysbiosis and consequent metabolic dysfunction, particularly reduced SCFA production, may play a role in LNTB pathophysiology. Because SCFAs and related anti-inflammatory commensal bacteria appear diminished in LNTB, restoring these microbial functions could represent a novel therapeutic target for disease management. This work opens a new avenue for considering the gut-immune axis in tuberculosis affecting lymph nodes, beyond the traditional focus on pulmonary disease.